Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

被引：1
|
作者：
Moik, F. [1 ,2 ]
Riedl, J. M. [2 ]
Ay, C. [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, Div Haematol & Haemostaseol, Vienna, Austria
[2] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 03期
关键词：
D O I：
10.1016/j.annonc.2023.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [41] Tepotinib plus osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
    Mazieres, J.
    Kim, T. M.
    Lim, B. K.
    Wislez, M.
    Dooms, C.
    Finocchiaro, G.
    Hayashi, H.
    Liam, C. K.
    Raskin, J.
    Tho, L. M.
    de Marinis, F.
    Nadal, E.
    Smit, E.
    Le, X.
    Brutlach, S.
    Grupp, A. M. O'Brate
    Adrian, S.
    Ellers-Lenz, B.
    Karachaliou, N.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1419 - S1420
  • [42] Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
    Leighl, Natasha B.
    Akamatsu, Hiroaki
    Lim, Sun Min
    Cheng, Ying
    Minchom, Anna Rachel
    Marmarelis, Melina Elpi
    Sanborn, Rachel E.
    Yang, James Chih-Hsin
    Liu, Baogang
    John, Tom
    Massuti, Bartomeu
    Spira, Alexander I.
    Xie, John
    Ghosh, Debropriya
    Alhadab, Ali
    Verheijen, Remy B.
    Gamil, Mohamed
    Bauml, Joshua Michael
    Baig, Mahadi
    Passaro, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8505 - LBA8505
  • [43] Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study
    Planchard, D.
    Feng, P-H.
    Karaseva, N.
    Kim, S-W.
    Kim, T. M.
    Lee, C. K.
    Poltoratskiy, A.
    Yanagitani, N.
    Powar, S.
    Huang, X.
    Howarth, P.
    Janne, P.
    Kobayashi, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S888 - S888
  • [44] Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.
    Gandara, David R.
    Von Pawel, Joachim
    Sullivan, Richard N.
    Helland, Aslaug
    Han, Ji-Youn
    Aix, Santiago Ponce
    Rittmeyer, Achim
    Barlesi, Fabrice
    Kubo, Toshio
    Park, Keunchil
    Goldschmidt, Jerome H.
    Gandhi, Mayank
    Yun, Cindy
    Yu, Wei
    Matheny, Christina
    He, Pei
    Sandler, Alan
    Ballinger, Marcus
    Fehrenbacher, Louis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
    Cho, Byoung Chul
    Goldman, Jonathan
    Leighl, Natasha
    De Braud, Filippo
    Lee, Ki Hyeong
    Ghiringhelli, Francois
    Garrido, Pilar
    Peguero, Julio
    Besse, Benjamin
    Cassier, Philippe
    Girard, Nicolas
    de Miguel, Maria
    Alvarez, Rosa
    Greystroke, Alastair
    Ohe, Yuichiro
    Hsia, Te-Chun
    Curtin, Joshua C.
    Chowdhury, Sanjib
    Lyu, Xuesong
    Gao, Grace
    Qu, Siyang
    Lorenzini, Patricia
    Kapoor, Aastha
    Kim, Priya
    Baig, Mahadi
    Thayu, Meena
    Knoblauch, Roland E.
    Hiret, Sandrine
    Tomasini, Pascale
    CANCER RESEARCH, 2024, 84 (07)
  • [46] Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial
    Rashdan, Sawsan
    Sampath, Sagus
    Iyengar, Puneeth
    Dowell, Jonathan
    Ahn, Chul
    Westover, Kenneth D.
    Zhang, Yuanyuan
    Cole, Suzanne
    Massarelli, Erminia
    Amini, Arya
    Koczywas, Marianna
    Gerber, David E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Durvalumab in ≥ 3rd-line EGFR mutant/ALK1, locally advanced or metastatic NSCLC: Results from the phase 2 ATLANTIC study
    Garassino, M. C.
    Cho, B-C.
    Gray, J. E.
    Mazieres, J.
    Park, K.
    Soo, R. A.
    Dennis, P.
    Huang, Y.
    Wadsworth, C.
    Rizvi, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK plus non-small-cell lung cancer (NSCLC)
    Novello, S.
    Mazieres, J.
    Oh, I-J.
    de Castro, J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    Kotb, A.
    Zeiter, A.
    Cardona, A.
    Balas, B.
    Johannsdottir, H.
    Das-Gupta, A.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
    Zhao, Hongyun
    Zhang, Zhonghan
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Yang, Yunpeng
    Zhang, Yang
    Huang, Yan
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
    Lu, S.
    Wu, L.
    Jian, H.
    Cheng, Y.
    Wang, Q.
    Fang, J.
    Wang, Z.
    Hu, Y.
    Sun, M.
    Han, L.
    Miao, L.
    Ding, C.
    Cui, J.
    Li, B.
    Li, X.
    Wang, K.
    Cang, S.
    Pan, Y.
    Ye, F.
    Liu, A.
    ANNALS OF ONCOLOGY, 2022, 33 (01) : 112 - 113
12345